{"paper_id":"b0761947-efc7-4403-ba21-e006acbc965a","body_text":"Abstract\nWe present a case of endometrioid adenocarcinoma arising from extragonadal endometriosis 18 years after total abdominal hysterectomy with bilateral salpingo-oophorectomy. After the primary surgery the patient received 11 years of unopposed oestrogen hormone replacement therapy. She presented with symptoms of urinary retention and pelvic mass. Following resection, histopathology identified the mass as an endometrioid adenocarcinoma. The association between persistent endometriosis and the development of endometrial cancer are discussed here together with the risks of unopposed oestrogen in the development of such lesions.\nBACKGROUND\nThere are a number of reports of endometrial carcinoma arising from deposits of endometriosis in women who have undergone hysterectomy and salpingo-oophorectomy for benign gynaecological indications. Those previously reported have been associated with oestrogen hormone replacement therapy (HRT), and have occurred within a short period after surgery. This case highlights that carcinoma can arise in endometriotic deposits up to 18 years after primary surgery and 7 years after cessation of oestrogen HRT. In addition, this case reminds clinicians that carcinoma in endometriotic deposits should be considered as a differential diagnosis in a female patient presenting with abdominal mass, particularly if she has received unopposed oestrogen HRT.\nCASE PRESENTATION\nA 58-year-old woman presented with right loin pain, a palpable suprapubic mass, and urinary retention. She had a history of total abdominal hysterectomy (TAH) and bilateral salpingo-oophorectomy (BSO) for endometriosis 18 years previously. She had two uncomplicated pregnancies, normal cervical cytology, and no other significant past medical history. She had no family history of cancer. After the TAH and BSO she received oestrogen only HRT for 11 years. The interval between cessation of HRT and presentation was 7 years.\nINVESTIGATIONS\nUltrasonography and computed tomography (CT) scan revealed a 14×12×11 cm cystic mass with bilateral hydronephrosis. The mass was multilocular with nodulations: recto-sigma compression and bilateral distal ureteric obstruction. Diagnostic laparoscopy confirmed a central pelvic mass, with appearance of endometriotic cyst, covered by bowel (fig 1A). There were multiple haemosiderin deposits on the anterior abdominal wall (fig 1A).\nDIFFERENTIAL DIAGNOSIS\nIn our case the differential diagnosis was between: (1) endometrioma; (2, 3) remnant of ovary and ovarian cyst/cancer; (4) bowel related mass; (5) bladder related mass. The last two were excluded by CT and laparoscopy.\nTREATMENT\nThe mass was removed at laparotomy and sigmoid colectomy was performed to resect the involved large bowel. The patient made a good postoperative recovery, and is having chemotherapy.\nOUTCOME AND FOLLOW-UP\nHistological assessment revealed an endometriotic cyst with adjacent nodules containing moderately differentiated endometrioid adenocarcinoma (fig 1B). Microscopically, the carcinoma was adjacent to an endometriotic cyst, with evidence of surrounding fibrosis. The tumour deposits were morphologically consistent with endometrioid adenocarcinoma (fig 1C), being cytokeratin-7 and vimentin positive and negative for carcino-embryonic antigen (CEA) (fig 1F–H), and also cytokeratin 20 negative (usually positive in all primary colonic carcinomas but negative in endometrioid).\nThe patient is being regularly followed up by an oncologist and a surgeon.\nImmediately after surgery she had a six cycles of chemotherapy with carboplatin. Nine months after surgery and being symptom-free there was an increase of CA125. Fourteen month post-surgery she developed symptoms and there was evidence on magnetic resonance imaging (MRI) of pelvic mass with liver metastases. She had further five cycles with carboplatin and caelyx. Now, 22 months after her surgery she have just started another chemotherapy cycle with treosulfan and gemcitabine. This is only a palliative treatment.\nDISCUSSION\nThis case complies with Sampson’s criteria for malignancy arising from endometriosis, which are (1) endometriosis and malignant tissue in a close proximity; (2) no other localisation of primary tumour; and (3) the histology is of endometrial origin. Therefore, we conclude that the endometrioid adenocarcinoma presented herein arose from an endometriotic deposit.\nThere is increasing evidence that endometriosis is associated with an increased risk of some cancers, particularly in the ovary,1–5 but also with breast cancer6,7 and non-Hodgkin’s lymphoma.8 There are fewer reported cases where adenocarcinoma occurred in endometriotic deposits after TAH and BSO. Brooks et al9 reviewed the literature in 1977, describing 45 cases of adenocarcinoma in extragonadal endometriosis, only three of which had previous hysterectomy and BSO. In 1997, Gücer et al10 reviewed cases of adenocarcinoma in endometriotic deposits, investigating cases treated with HRT; 20 cases were described, 17 of which had BSO (one of which was already presented in Brooks series). Since 2000, there have been 14 published cases of endometrioid adenocarcinoma arising in endometriosis following unopposed oestrogen HRT (table 1). However, the majority of these cases were taking HRT at the time of diagnosis. Our case appears to be more unusual, where there is a longer duration between administration of unopposed oestrogen and the development of adenocarcinoma.\nTable 1.\n| Author | Reference | No. of cases | Duration of hormone replacement therapy (HRT) | Interval between HRT and diagnosis of cancer |\n| Eckert and Eckert | Am Fam Physician 2000;62:734–6 | 1 | 27 years unopposed oestrogen | Current |\n| Debus and Schmacher | Acta Obstet Gynecol Scand 2001;80:589–90 | 1 | 17 years unopposed oestrogen | Current |\n| Lavery and Gilmer | BJOG 2001;108:1106–7 | 2 | (1) 14 years unopposed oestrogen (tablets then patches) | Both current users |\n| (2) 3 years unopposed oestrogen patch | ||||\n| Petersen et al | Histopathology 2002;40:171–6 | 2 | (1) 9 years unopposed oestrogen | (1) 5 year interval |\n| (2) 4 years unopposed oestrogen | (2) Current user | |||\n| Soliman and Evans | J Br Menopause Soc 2004;10:123–4 | 2 | (1) 3 years previously | Both current users |\n| (2) 13 years previously | ||||\n| Kawate et al | Jpn J Clin Oncol 2005;35:154–7 | 1 | 14 years unopposed oestrogen | Current |\n| Somoye and Gull | J Obstet Gynaecol 2005;25:220–1 | 1 | 20 years unopposed oestrogen | Current |\n| Nomura et al | Acta Obstet Gynecol Scand 2006;85:1019–21 | 1 | 7 months combined HRT, 15 months unopposed oestrogen | Current |\n| Areia et al | Eur J Gynaecol Oncol 2004;25:255–6 | 1 | 6 years unopposed oestrogen | Current |\n| Fat et al | Gynecol Obstet Fertil 2008;36:51–5 | 1 | 11 years unopposed oestrogen | Current |\n| Al-Talib | Saudi Med J 2008;29:1044–7 | 1 | 13 years unopposed oestrogen | Current |\nThe hypothesis that unopposed oestrogen as given in some HRT regimens may lead to the development of cancer in endometriotic deposits is biologically plausible, as oestrogens lead to proliferation of endometrial tissue. Indeed, oestrogen only HRT is contraindicated in women without hysterectomy due to the increased risk of endometrial carcinoma. In this case a causative association between exogenous oestrogen and the development of adenocarcinoma is difficult to affirm since there was a 7 year interval between cessation of HRT and the development of symptoms. Endometriosis does not require hormonal stimuli to persist per se and spontaneous malignant transformation may have happened within this period of time.\nIn conclusion, where endometriosis remains after hysterectomy, each patient requires individual assessment and counselling regarding their risk of malignancy if they require HRT.\nLEARNING POINTS\nCarcinoma can occur in endometriotic deposits even after a long interval after hysterectomy.\nCarcinoma in deposits of endometriosis should be regarded as a rare, but possible, differential diagnosis in women presenting with an abdominal or pelvic mass after hysterectomy.\nHRT should be used cautiously in cases where endometriosis remains after surgery. Where HRT is required, combined HRT is recommended although the evidence base is weak.11\nA multidisciplinary approach with involvement of radiologists and surgeons is crucial in such cases.\nFootnotes\nCompeting interests: none.\nPatient consent: Patient/guardian consent was obtained for publication\nREFERENCES\n- 1.Nezhat F, Datta MS, Hanson V, et al. The relationship of endometriosis and ovarian malignancy: a review. Fertil Steril 2008; 90: 1559–70 [DOI] [PubMed] [Google Scholar]\n- 2.Viganò P, Somigliana E, Parazzini F, et al. 2007. Bias versus causality: interpreting recent evidence of association between endometriosis and ovarian cancer. Fertil Steril 2007; 88: 588–93 [DOI] [PubMed] [Google Scholar]\n- 3.Somigliana E, Vigano’ P, Parazzaini F, et al. Association between endometriosis and cancer: a comprehensive review and critical analysis of clinical and epidemiological evidence. Gynaecol Oncol 2006; 101: 331–41 [DOI] [PubMed] [Google Scholar]\n- 4.Van Gorp T, Amant F, Neven P, et al. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obtet Gynaecol 2004; 18: 349–71 [DOI] [PubMed] [Google Scholar]\n- 5.Modugo F, Ness RB, Allen GO, et al. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynaecol 2004; 191: 733–40 [DOI] [PubMed] [Google Scholar]\n- 6.Matalliotakis IM, Cakmak H, Mahutte N, et al. The familial risk of breast cancer in women with endometriosis from Yale series. Surg Oncol 2008; 17: 289–93 [DOI] [PubMed] [Google Scholar]\n- 7.Melin A, Sparen P, Bergqvist A. The risk of cancer and the role of parity among women with endometriosis. Hum Reprod 2007; 22: 3021–6 [DOI] [PubMed] [Google Scholar]\n- 8.Brinton LA, Gridley G, Persson I, et al. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynaecol 1997; 176: 572–9 [DOI] [PubMed] [Google Scholar]\n- 9.Brooks JJ, Wheeler JE. Malignancy arising in extragonadal endometriosis. A case report and summary of the world literature. Cancer 1977; 40: 3065–73 [DOI] [PubMed] [Google Scholar]\n- 10.Gücer F, Pieber D, Arikan MG. Malignancy arising in extra-ovarian endometriosis during estrogen stimulation. Eur J Gynaec Oncol 1998; 19: 39–41 [PubMed] [Google Scholar]\n- 11.Soliman NF, Hillard TC. Hormone replacement therapy in women with past history of endometriosis. Climacteric 2006; 9: 325–35 [DOI] [PubMed] [Google Scholar]","source_license":"CC0","license_restricted":false}